From Quiet Compounder to 2026 Breakout? BSEM

See why Zacks Has a Huge Price Target! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.   Bio Stem Technologies Accelerates Into 2026 With Transformative Acquisition, Seven Straight Profitable Quarters, and Entry into Advanced and Acute Wound Care Markets! BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings' surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care.  With established product lines like Neox® and Clarix®, a nationwide sales force, and key GPO contracts, BioStem is now positioned to capture a $300–$350 million addressable market, spanning chronic and acute wound care, burns, and soft-tissue repair.  Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company's profitable growth, clinical validation, and expanding market presence. Coupled with seven consecutive profitable quarters, strong gross margins of 88.5%, and $16 million in cash post-acquisition, BSEM is demonstrating operational excellence rarely seen in small-cap regenerative medicine.  Backed by clinically validated BioREtain® technology, FDA-level studies, and a potential Nasdaq uplisting in mid-2026, BSEM is gaining traction with both institutional investors and healthcare providers. Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency. This communication should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 02/02/2026. Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today's Bonus Content: Buy AES Immediately